Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Antibiotic launched for hard to treat hospital infections

  • 1 Comment

A new antibiotic has been launched for treating complicated skin and soft tissue infections in hospitals and community acquired pneumonia.

Ceftaroline (Zinforo) has been developed specifically to tackle difficult to treat infections including MRSA in complicated skin and soft tissue infections and pneumococcal infection in community acquired pneumonia.

It was launched in the UK this week by manufacturer AstraZeneca and will cost £375 for a pack of 10 vials.

David Livermore, professor of medical microbiology at the University of East Anglia, said: “Although the number of MRSA bacteraemias in England has reduced by over 80% since its peak in 2003, MRSA remains an important cause of infection and continues to pose a serious health threat. 

“It is therefore encouraging to see new treatment options for patients, such as ceftaroline – which is effective against MRSA in complicated skin and soft tissue infections – becoming available.”

  • 1 Comment

Readers' comments (1)

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.